MENLO PARK, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced one oral presentation and nine data poster presentations at the Infectious Disease Society of American (IDSA) IDWeek 2022 Conference from October 19-24, 2022 in Washington D.C. highlighting new data for epetraborole. AN2 Therapeutics is currently enrolling patients in its pivotal Phase 2/3 clinical trial evaluating once-daily, oral epetraborole for treatment-refractory Mycobacterium avium complex (MAC) lung disease, the most common form of nontuberculous mycobacterial (NTM) lung disease. Symposium: New Antimicrobials and ID Diagnostics in the Pipeline #1
Date: Thursday, October 20, 2022 from 8:00-9:00am ET
Presenter: Paul Eckburg, M.D.
Title: Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies Date: Thursday, October 20, 2022 from 12:15-1:30pm ET
Date: Thursday October 20, 2022 from 12:15-1:30pm ET
Poster Session: A2. PK/PD studies
Title: Dose-response Studies of the Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, Epetraborole, in the Intracellular Hollow Fiber System Model of Mycobacterium avium Complex Lung Disease Date: Saturday, October 22, 2022 from 12:15-1:30pm ET
Poster Session: A1. Antimicrobial Novel Agents
Date: Saturday, October 22, 2022 from 12:15-1:30pm ET
Poster Session: A1. Antimicrobial Novel Agents
Date: Saturday, October 22, 2022 from 12:15-1:30pm ET
Poster Session: A1. Antimicrobial Novel Agents
Title: In Vitro Activities of Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, in Drug Combinations Against Nontuberculous Mycobacteria Including Resistance Frequency and MIC Characterization of Mycobacterium avium ATCC 700898 Epetraborole-resistant Mutants Date: Saturday, October 22, 2022 from 12:15-1:30pm ET
Poster Session: A1. Antimicrobial Novel Agents
Date: Saturday, October 22, 2022 from 12:15-1:30pm ET
Poster Session: A1. Antimicrobial Novel Agents
Date: Saturday, October 22, 2022 from 12:15-1:30pm ET
Poster Session: A1. Antimicrobial Novel Agents
Title: Tolerability and Pharmacokinetics of Oral Epetraborole at the Predicted Therapeutic Dosage for Mycobacterium avium Complex (MAC) Lung Disease: A Phase 1b Dose-ranging and Food Effect Study Date: Saturday, October 22, 2022 from 12:15-1:30pm ET
Poster Session: A1. Antimicrobial Novel Agents
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our lead candidate is epetraborole, which we are studying in a pivotal Phase 2/3 trial as a once-daily, oral treatment with a novel mechanism of action for patients with NTM lung disease, a rare, chronic, and progressive infectious disease caused by bacteria, known as mycobacteria, that leads to irreversible lung damage and can be fatal. For more information, please visit our website at www.an2therapeutics.com. l.day@an2therapeutics.com
INVESTOR AND MEDIA CONTACT: